Effect of Atorvastatin combined with Irbesartan in the treatment of early diabetic nephropathy

Xiaojing Zhong; Jiajia Fan

doi:10.12669/pjms.40.7.9214

Xiaojing Zhong
Jiajia Fan Huzhou Central Hospital

DOI: https://doi.org/10.12669/pjms.40.7.9214

Keywords: Atorvastatin, Irbesartan, Early diabetes nephropathy

Abstract

Objective: To explore the effect of Atorvastatin combined with Irbesartan in the treatment of early diabetic nephropathy (DN).

Methods: Clinical data from 153 patients with early DN, admitted to Huzhou Central Hospital from January 2020 to December 2022, was retrospectively selected. Patients were divided into two groups based on the treatment they received: patients received Irbesartan treatment alone were assigned to Irbesartan group (n=74); patients received Irbesartan combined with Atorvastatin were assigned to combined group (n=79). Levels of renal function indicators, renal fibrosis indicators, micro inflammatory status indicators, and incidence of adverse reactions were compared between the two groups before and after the treatment.

Results: After the treatment, indicators of renal function, renal fibrosis and micro-inflammation in both groups significantly decreased compared to pretreatment levels (P<0.05), and were significantly lower in the combined group compared to Irbesartan group (P<0.05). There was no significant difference in the incidence of adverse reactions between the groups (P>0.05).

Conclusions: Compared with Irbesartan alone, Atorvastatin combined with Irbesartan is more effective in the treatment of early DN. Combined treatment regimen is able to effectively reduces the micro-inflammatory state, improve renal function and fibrosis, and is not associated with the increased risk of adverse reactions.

doi: https://doi.org/10.12669/pjms.40.7.9214

How to cite this: Zhong X, Fan J. Effect of Atorvastatin combined with Irbesartan in the treatment of early diabetic nephropathy. Pak J Med Sci. 2024;40(7):1410-1414. doi: https://doi.org/10.12669/pjms.40.7.9214

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.